Login to Your Account

Pharma: Other News To Note

Wednesday, March 7, 2012
• Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for review a resubmission of a new drug application for perampanel (E2007) for partial onset seizures of epilepsy. Perampanel is an oral alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor antagonist.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription